Skip to content
Endologix is now Rhevera Medical. Learn more about our evolution.
Peripheral
Pounce System
DETOUR System
DETOUR System Reimbursement
DETOUR Professional Education
For PAD Patients
Find a Doctor
Aortic
AAA
ALTO
AFX2
EVAR for Women
EVAR Portfolio Resources
Clinical Evidence
Procedural Training
IFUs
About Us
About Rhevera
News
The Team
Careers
Internal Applicant Portal
External Applicant Portal
Investigator-Initiated Research
Contact Us
Peripheral
Pounce System
DETOUR System
DETOUR System Reimbursement
DETOUR Professional Education
For PAD Patients
Find a Doctor
Aortic
AAA
ALTO
AFX2
EVAR for Women
EVAR Portfolio Resources
Clinical Evidence
Procedural Training
IFUs
About Us
About Rhevera
News
The Team
Careers
Internal Applicant Portal
External Applicant Portal
Investigator-Initiated Research
Contact Us
Search
Back to News
January 29, 2018
Endologix Appoints Greg Morrow as Chief Marketing Officer and Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Prev
Previous
VEITH 2017 Presentation: Status of the LEOPARD Trial: Comparing the AFX Endologix Graft to other Standard EVAR Endografts
Next
Endologix LLC Completes Patient Enrollment in the ELEVATE IDE Clinical Study
Next
